GlassScriptPhysician profile
Page V Salenger
NPI 1295737609
$1,911.79
in general payments reported to CMS, 2019-2025
28 companies · $750 in 2025
The $750 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.89 · 2021: $78.91 · 2023: $401 · 2024: $599 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $185.29 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Akebia Therapeutics INC | $175.00 | 2025 | Vafseo |
| Calliditas Therapeutics US INC. | $171.77 | 2024-2025 | Tarpeyo |
| Amgen INC. | $168.42 | 2024-2025 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $161.20 | 2023-2025 | Terlivaz, Acthar |
| Vantive US Healthcare LLC | $122.77 | 2025 | Renal - Chronic, Renal - Pd |
| Baxter Healthcare | $120.01 | 2019-2021 | |
| Lilly USA, LLC | $113.02 | 2023-2024 | Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $104.50 | 2023-2024 | Jynarque, Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.97 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $62.24 | 2024-2025 | |
| Glaxosmithkline, LLC. | $60.97 | 2024-2025 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $44.37 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $35.48 | 2023-2025 | Lokelma, Farxiga |
| Sumitomo Pharma America, INC. | $34.52 | 2024 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.89 | 2025 | |
| Nxstage Medical, INC. | $26.03 | 2019 | |
| Alexion Pharmaceuticals, INC. | $25.93 | 2024 | Ultomiris |
| Lundbeck LLC | $23.49 | 2023 | Rexulti |
| Fresenius USA Marketing, INC. | $21.86 | 2025 | Velphoro |
| Collegium Pharmaceutical, INC. | $20.92 | 2023 | Xtampza |
| Regeneron Healthcare Solutions, INC. | $17.97 | 2023 | Evkeeza |
| Pfizer INC. | $15.77 | 2023 | |
| Vifor Pharma, INC. | $15.76 | 2021 | |
| Axsome Therapeutics, INC. | $15.15 | 2023 | Auvelity |
| Currax Pharmaceuticals LLC | $14.81 | 2023 | Contrave, Onzetra Xsail |
| Novo Nordisk INC | $14.40 | 2023 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $13.28 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Page Salenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.